Carcinogenesis Advance Access originally published online on September 3, 2007
Carcinogenesis 2007 28(12):2491-2500; doi:10.1093/carcin/bgm195
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The type III TGF-β receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation
1 Department of Medicine
2 Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
* To whom correspondence should be addressed. Tel: +1 919 668 1352; Fax: +1 919 668 2458; Email: blobe001{at}mc.duke.edu
Transforming growth factor β (TGFβ) has an important role as a negative regulator of cellular proliferation. The type III transforming growth factor β receptor (TβRIII) has an emerging role as both a TGFβ superfamily co-receptor and in mediating signaling through its cytoplasmic domain. In L6 myoblasts, TβRIII expression enhanced TGFβ1-mediated growth inhibition, with this effect mediated, in part, by the TβRIII cytoplasmic domain. The effects of TβRIII were not due to altered ligand presentation or to differences in Smad2 phosphorylation. Instead, TβRIII specifically increased Smad3 phosphorylation, both basal and TGFβ-stimulated Smad3 nuclear localization and Smad3-dependent activation of reporter genes independent of its cytoplasmic domain. Conversely, SB431542, a type I transforming growth factor β receptor (TβRI) inhibitor, as well as dominant-negative Smad3 specifically and significantly abrogated the effects of TβRIII on TGFβ1-mediated inhibition of proliferation. TβRIII also specifically increased p38 phosphorylation, and SB203580, a p38 kinase inhibitor, specifically and significantly abrogated the effects of TβRIII/TGFβ1-mediated inhibition of proliferation in L6 myoblasts and in primary human epithelial cells. Importantly, treatment with the TβRI and p38 inhibitors together had additive effects on abrogating TβRIII/TGFβ1-mediated inhibition of proliferation. In a reciprocal manner, short hairpin RNA-mediated knockdown of endogenous TβRIII in various human epithelial cells attenuated TGFβ1-mediated inhibition of proliferation. Taken together, these data demonstrate that TβRIII contributes to and enhances TGFβ-mediated growth inhibition through both TβRI/Smad3-dependent and p38 mitogen-activated protein kinase pathways.
Abbreviations: GIPC, GAIP-interacting protein, C-terminus; HEPES, N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; HMEC, human mammary epithelial cell; MAPK, mitogen-activated protein kinase; NOSE, normal ovarian surface epithelial; PI3K, phosphatidylinositol 3-kinase; shRNA, short hairpin RNA; TGFβ, transforming growth factor β; TβRI, type I transforming growth factor β receptor; TβRII, type II transforming growth factor β receptor; TβRIII, type III transforming growth factor β receptor
Received July 3, 2007; revised August 15, 2007; accepted August 17, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Margulis, T. Maity, X.-Y. Zhang, S. J. Cooper, J. A. Copland, and C. G. Wood Type III Transforming Growth Factor-{beta} (TGF-{beta}) Receptor Mediates Apoptosis in Renal Cell Carcinoma Independent of the Canonical TGF-{beta} Signaling Pathway Clin. Cancer Res., September 15, 2008; 14(18): 5722 - 5730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Kirkbride, T. A. Townsend, M. W. Bruinsma, J. V. Barnett, and G. C. Blobe Bone Morphogenetic Proteins Signal through the Transforming Growth Factor-{beta} Type III Receptor J. Biol. Chem., March 21, 2008; 283(12): 7628 - 7637. [Abstract] [Full Text] [PDF]
|
|